Our approach to drug discovery and development is to systematically target post-transcriptional control processes that can be modulated by small-molecule therapeutics. We believe that focusing on post-transcriptional control processes has substantial advantages:
- Address known drug targets through new mechanisms of action
- Pursue a broad range of targets that have previously not been amenable to drug discovery
- Target a large number of unexploited post-transcriptional control drug targets
- Address intractable drug targets in a wide variety of diseases for which there is an unmet medical need, including genetic disorders, cancer, and musculoskeletal disorders, as well as inflammation, metabolic disorders, cardiovascular conditions and neurological disorders.